Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open‐label, single‐arm study
Epilepsia Open · 2024-04 · 9 (2) · 522-533
DOI: 10.1002/epi4.12875 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia Open, online erschienen am 11.01.2024. Verfasst von Ronit Pressler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurophysiology, Great Ormond Street Hospital and Clinical Neuroscience, UCL-GOS Institute of Child Health, London, UK. Hauptthemen laut MEDLINE: Anticonvulsants, Seizures, Pyrrolidinones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Objective
To evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) in neonates with repeated electroencephalographic seizures not controlled with previous antiseizure medications (ASMs).
Methods
Phase 2/3, multicenter, open‐label, single‐arm study (N01349/NCT03325439) in neonates with repeated electroencephalographic seizures (lasting ≥10 s) confirmed by video‐electroencephalography, and inadequate seizure control with at least one ASM. A screening period (up to 36 h) was followed by a 48‐h evaluation period during which patients received 0.5 mg/kg BRV twice daily (b.i.d) intravenously (IV). Patients who benefitted from BRV (investigator's opinion) could continue 0.5 mg/kg b.i.d (IV or oral solution) in an extension period. Outcomes included plasma concentrations of BRV following the first dose (primary), and incidence of treatment‐emergent adverse events (TEAEs).
Results
Six patients (median [range] postnatal age: 1.5 [1.0, 6.0] days) received ≥1 dose of BRV. All six patients completed the evaluation period; two entered and completed the extension period. Overall (evaluation and extension periods), three patients received one dose of 0.5 mg/kg BRV and three received more than one dose. The median (range) duration of exposure to BRV (IV and oral solution) was 1.5 (1.0, 29.0) days ( n = 6). At 0.5–1, 2–4, and 8–12 h following IV BRV administration, the GeoMean (GeoCV) plasma concentrations of BRV were 0.53 mg/L (15.40% [ n = 5]), 0.50 mg/L (28.20% [ n = 6]), and 0.34 mg/L (13.20% [ n = 5]), respectively. Individual and population BRV PK profiles were estimated, and individual PK parameters were calculated using Bayesian feedback. The observed concentrations were consistent with the predicted PK. Three patients experienced four TEAEs, none of which were considered related to BRV. Significance BRV plasma concentrations in neonates were consistent with data in older children receiving BRV oral solution, and with data from adults receiving a nominal IV dose of 25 mg b.i.d. BRV was well tolerated, with no drug‐related TEAEs reported. Plain Language Summary Few drugs are available to treat seizures in newborn babies. Brivaracetam is approved to treat focal‐onset seizures in children and adults in Europe (patients 2 years of age and older) and the United States (patients 1 month of age or older). In this study, six newborns with repeated seizures were treated with intravenous brivaracetam. The study doctors took samples of blood from the newborns and measured the levels of brivaracetam. The concentrations of brivaracetam in the newborns’ blood plasma were consistent with data from studies in older children and in adults. No brivaracetam‐related medical problems were reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neurophysiology, Great Ormond Street Hospital and Clinical Neuroscience, UCL-GOS Institute of Child Health, London, UK.
- INFANT Research Centre and Department of Paediatrics and Child Health, Cork, Ireland.
- Department of Neuropediatrics and Muscle Disorders, Medical Center, University of Freiburg, Freiburg, Germany.
- UCB Pharma, Braine-l'Alleud, Belgium.
- UCB Pharma, Monheim am Rhein, Germany.
- UCB Pharma, Morrisville, North Carolina, USA.
ORCID-Profile: Ronit Pressler, Kerstin Alexandra Klotz
Förderung
- UCB Pharma
Zitieren
APA
Pressler, R., Boylan, G., Dempsey, E., Klotz, K. A., Krauwinkel, W., Will, E., Morita, D., Floricel, F., Elshoff, J. P., & van den Anker, J. (2024). Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open‐label, single‐arm study. Epilepsia Open, 9(2), 522-533. https://doi.org/10.1002/epi4.12875
Vancouver
Pressler R, Boylan G, Dempsey E, Klotz KA, Krauwinkel W, Will E, et al. Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open‐label, single‐arm study. Epilepsia Open. 2024;9(2):522-533. doi:10.1002/epi4.12875
BibTeX
@article{Pressler2024,
author = {Pressler, Ronit and Boylan, Geraldine and Dempsey, Eugene and Klotz, Kerstin Alexandra and Krauwinkel, Walter and Will, Edgar and Morita, Diego and Floricel, Florin and Elshoff, Jan-Peer and van den Anker, John},
title = {Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open‐label, single‐arm study},
journal = {Epilepsia Open},
year = {2024},
volume = {9},
number = {2},
pages = {522--533},
doi = {10.1002/epi4.12875}
}
EUVIMED